论文部分内容阅读
本文检测了1种新合成的环磷酰胺衍化物——mafosfamid(ASTA Z 7557)在体外消除自体骨髓移植物中急淋白血病细胞的能力。结果发现 mafes-famid 对 DNA 合成的抑制呈剂量依赖性。以 Na-malwa 细胞(1种有很高成斑率的原始淋巴细胞样白血病细胞株)为实验对象,分别以0、10、25、50、75、100μg/ml 浓度的 mafosfamid 处理10~6个这种细胞,其所达到的对数杀灭依次为:0、0.1、2.5、4.5、4.5、4.8。而且这种杀灭与肿瘤靶细胞的浓度无关。当用50—100μg/ml mafosfamid 处理,在急淋细胞与骨髓细胞的比例为1:100的混合细胞中可消除肿瘤细
This article examined the ability of a newly synthesized cyclophosphamide derivative, mafosfamid (ASTA Z 7557), to eliminate acute leukemia cells in autologous bone marrow transplants in vitro. The results showed that the inhibition of DNA synthesis by mafes-famid was dose-dependent. Na-malwa cells (a primary lymphoblastic leukemia cell line with high spotting rate) were treated with 10 to 6 mafosfamid concentrations of 0, 10, 25, 50, 75, and 100 μg/ml, respectively. The number of logarithmic killings of these cells was: 0, 0.1, 2.5, 4.5, 4.5, 4.8. And this killing has nothing to do with the concentration of tumor target cells. When treated with 50-100 μg/ml mafosfamid, tumors can be eliminated in mixed cells with a 1:100 ratio of acute lymphocytic and myeloid cells.